Organogenesis Hldgs Stock (NASDAQ:ORGO), Trade Ideas

Organogenesis Hldgs

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.

Organogenesis Holdings

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACNT

ARBB

ASST

BAOS

BCLI

BETS

BJDX

CHRS

CING

COIN

CYTK

ELTX

EWTX

FWBI

GDHG

HALL

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

IOVA

JTAI

JZXN

LIDR

MGAM

MOBX

MTNB

MYND

NUKK

ONCT

ORGO

RPHM

SMFL

VLCN

VNCE

VRAX

WULF

Shares of  Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition proposal to acquire 100% of equity of the company for $1.80 per share.

Reneo Pharmaceuticals shares climbed 13.6% to $1.59 on Wednesday.

Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Price Target

Analyst Ratings

ASPN

EXPE

FUSN

MELI

MIST

PINS

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Meta To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday

ACAD

ACIC

ADTX

ANZU

ASTI

AXLA

AYTU

BNOX

BXRX

CGRN

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

CNXC

CVAC

EDSA

GNSS

GRTS

INPX

JEWL

MCLD

OPRA

PIXY

PRTC

RNLX

SASI

SLNO

SPRC

STRC

SYBX

TURB

USAC

WDAY

XWEL

Gainers


	Bionomics Limited  (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks.


Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Organogenesis Holdings Inc

Edward Snowden offered a sarcastic commentary on President Joe Biden&#8217;s visit to a Wawa in Philadelphia.
What Happened: On Thursday, Snowden took to X, formerly Twitter, to share his views on Biden&#8217;s recent visit to a Wawa convenience store in Philadelphia. His tweet, &#8220;It&#8217;s like watching jordan at the top of his game,&#8221; was a tongue-in-cheek comparison of the President&#8217;s visit to the performance of a top athlete.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">it&#39;s like watching jordan at the top of his game <a href="https://t.co/TmmCTMaO8L">https://t.co/TmmCTMaO8L</a>
&mdash; Edward Snowden (@Snowden) <a href="https://twitter.com/Snowden/status/1781126516241240575?ref_src=twsrc%5Etfw">April 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Biden made a stop at Wawa in Center City near Independence Hall, accompanied by Philadelphia Mayor Cherelle Parker. 
Biden ordered an Italian hoagie and a black and white milkshake from the convenience store, while Parker chose yogurt. This marked Biden&#8217;s third stop in Pennsylvania that week, as he prepared for a rematch against former President Donald Trump, <a href="https://www.cbsnews.com/philadelphia/news/joe-biden-in-philadelphia-wawa/">reported</a> CBS News.
He also received endorsements from members of Robert F. Kennedy Jr.&#8217;s family and made previous visits to Scranton and Pittsburgh, discussing economic policies and meeting with union leaders.
See Also: <a href="https://www.benzinga.com/news/24/04/38263998/trumps-niece-says-ex-presidents-mandatory-courtroom-presence-will-give-jury-front-row-seat-of-his-ba?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Niece Says Ex-President&#8217;s Mandatory Courtroom Presence Will Give Jury Front-Row Seat Of His Bad Behavior: &#8216;Donald Is Finally Confronting His Criminal Charges&#8217;</a>
Why It Matters: Snowden&#8217;s tweet comes in the context of his previous criticisms of Biden. In February, he expressed concern over reports that <a href="https://www.benzinga.com/news/24/02/37384159/edward-snowden-isnt-happy-biden-skipped-cognitive-testing-during-medical-exam-white-house-medical-st">Biden had skipped a cognitive assessment</a> during his annual physical. Snowden suggested that the White House medical staff has historically been &#8220;all-too-happy to lie&#8221; to downplay or conceal Presidential health issues.
While Snowden has been vocal about his views on the current administration, he has previously dismissed the idea of running for President himself. In a response to a Twitter user&#8217;s question in June 2023, he stated, &#8220;<a href="https://www.benzinga.com/23/06/32959023/president-edward-snowden-heres-what-the-whistleblower-has-to-say-about-that">I&#8217;d rather not</a>.&#8221;
Photo via Wikimedia
Read Next: <a href="https://www.benzinga.com/news/24/04/38270988/elon-musk-reacts-after-trump-posts-screenshot-of-tesla-ceos-post-about-lawfare-not-being-applied-equ?itm_source=parsely-api">Elon Musk Reacts After Trump Posts Screenshot Of Tesla CEO&#8217;s Post About &#8216;Lawfare:&#8217; &#8216;Not Being Applied Equally To Joe And Hunter Biden&#8217;</a>
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Shivdeep Dhaliwal</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

Politics

General

Edward Snowden Compares Biden Ordering A Milkshake To 'Jordan At The Top Of His Game'

- Reuters Citing Iranian Press TV

Macro Economic Events

Global

Economics

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

Situation In Iran's Isfahan Is Normal, No Explosion Taken Place On Ground; Iran's Nuclear Facilities Remain Unharmed

Israeli Military Says Sirens Sounded In Northern Israel

Elon Musk, the CEO of Tesla Inc, weighed in on the recent Israeli airstrike targeting Iran and expressed his thoughts on the situation.
What Happened: Musk&#8217;s comments on X, formerly Twitter, were in response to a post by OSINTdefender, an Open Source Intelligence Monitor focusing on Europe and global conflicts.
The post by OSINTdefender reported that the Israeli Air Force may have targeted the 8th Tactical Airbase of the Iranian Air Force, which houses multiple squadrons of F-14 &#8220;Tomcat&#8221; fighter aircraft.
Musk&#8217;s post read, &#8220;Our tax dollars somehow also blowing up our tax dollars.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Our tax dollars somehow also blowing up our tax dollars
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1781141827757781162?ref_src=twsrc%5Etfw">April 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38306270/dogecoin-could-make-elon-musks-fate-loves-irony-comment-come-true-if-it-flips-ethereums-ma?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dogecoin Could Make Elon Musk&#8217;s &#8216;Fate Loves Irony&#8217; Comment Come True If It Flips Ethereum&#8217;s Market Cap At Last Bull Run, Says This Crypto Influencer</a>
Why It Matters: The Israeli airstrike comes in the wake of escalating tensions between <a href="https://www.benzinga.com/news/24/04/38240360/what-a-full-blown-war-between-israel-and-iran-could-entail-according-to-one-report">Iran and Israel</a>. Iran recently launched a large-scale missile and drone attack on Israel, reportedly in retaliation for an incident in Syria that resulted in the deaths of several Iranian officers.
Israel responded to the attack with a series of <a href="https://www.benzinga.com/news/24/04/38328006/israel-reportedly-strikes-iran-syria-iraq-in-retaliation-for-missile-drone-attack">alleged retaliatory strikes</a>, targeting Iran, Syria, and Iraq. This has led to a significant escalation of the conflict dynamics between the two countries, potentially edging towards <a href="https://www.benzinga.com/news/24/04/38240360/what-a-full-blown-war-between-israel-and-iran-could-entail-according-to-one-report">full-scale war</a>.
The U.S. has also intensified <a href="https://www.benzinga.com/markets/asia/24/04/38316947/us-intensifies-economic-pressure-on-iran-in-response-to-attack-on-israel-we-will-continue-to-deploy">economic pressure on Iran </a>in response to the attack on Israel, imposing new sanctions on a network of individuals and organizations involved in developing Iran&#8217;s Unmanned Aerial Vehicle (UAV) capabilities.
Amid these tensions, China has reaffirmed its <a href="https://www.benzinga.com/news/24/04/38267600/amid-iran-israel-tensions-china-affirms-support-for-tehran-strengthens-ties">support for Iran</a> and strengthened its bilateral ties with Tehran.
Read Next: <a href="https://www.benzinga.com/news/24/04/38288858/elon-musk-says-bring-it-on-after-russian-space-chief-touts-amur-rocket-says-it-can-be-reused-up-to-5?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Says &#8216;Bring It On&#8217; After Russian Space Chief Touts Amur Rocket, Says It Can Be Reused Up To 5X More Than SpaceX&#8217;s Falcon 9</a>
Image Via Shutterstock 
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Kaustubh Bagalkote</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/topic/kaustubh-bagalkote" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

TSLA

Elon Musk Reacts To Alleged Israeli Airstrike On Iran: 'Our Tax Dollars Somehow Also Blowing Up Our Tax Dollars'

Iranian Fars News Agency, 'The Sound Of Three Explosions Has Been Heard Near An Army Base In Northwest Isfahan'; Air Defense Systems Have Been Activated In Response To 'An Object Suspected To Be A Drone', Sources Say

<a href="https://www.reuters.com/world/middle-east/israeli-missiles-hit-site-iran-abc-news-reports-2024-04-19/">https://www.reuters.com/world/middle-east/israeli-missiles-hit-site-iran-abc-news-reports-2024-04-19/</a>
&nbsp;
A U.S. official confirmed to ABC News Israeli missiles have hit a site in Iran.
The official could not confirm whether Syria and Iraq sites were hit as well.
An explosion was heard in the city of Qahjavaristan, Isfahan, according to Iranian Media.
They also report that there has been a suspension of flights to Tehran, Isfahan and Shiraz.
Iran launched hundreds of missiles and drones into Israel last weekend. Israeli officials said the country's Iron Dome defense system endured a big test from Iran's attack on Saturday, intercepting 99% of the 300 "threats of various types" thrown at it.
Iran's Islamic Revolutionary Guard Corps, according to Israel Defense Forces spokesperson Daniel Hagari, launched 170 unmanned aerial vehicles (UAVs), more than 120 ballistic missiles and more than 30 cruise missiles in the attack.
Hagari said "99% of the threats launched towards Israeli territory were intercepted -- a very significant strategic achievement."
Hagari said the attack resulted in only one known Israeli casualty, a 7-year-old girl who was severely injured when she was struck by shrapnel apparently from an intercepted missile.

"Israel Retaliates As Missiles Strike A Site In Iran, US Officials Say" - ABC News

Cyberspace Administration Of China Ordered Removal Of Meta's WhatsApp And Threads Apps From China Storefront Based On National Security Concerns

Kentucky Governor Andy Beshear (D) unveiled plans on Thursday to utilize a lottery system for granting initial licenses to businesses vying for entry into the state&#8217;s medical marijuana industry.
Speaking at a press conference, Beshear called the lottery approach a fair way to give all qualifying applicants an equal opportunity to receive a license for the program, which is expected to launch in January 2025.
Set for this coming October, the lottery should remove any temptation to lobby to "get a leg up in different ways that we don't want to see," Beshear said at his weekly press conference, <a href="https://abcnews.go.com/Business/wireStory/kentucky-governor-announces-lottery-award-initial-round-medical-109402560">reported</a> ABC News.
"It reduces or eliminates litigation, and it creates a more fair process, not one where people bid against each other and only then the big companies can be a part of it," Beshear said. "But one that provides at least a chance for everyone who can meet the criteria."
Kentucky will initially issue 48 medical marijuana dispensary licenses, divided among 11 regions around the state as a way of ensuring the shortest possible drive times for Kentuckians with qualifying health conditions, said Sam Flynn, executive director of the medical cannabis program.
Each region will be allocated at least four dispensary licenses. Counties will be limited to one dispensary each except for those that include Louisville and Lexington, which can have two licenses, Flynn said. Limited numbers of cultivator and processor licenses will also be issued.
Beshear said capping the number of licenses is meant to avoid flooding the market with products and exceeding demand, which would ultimately hurt businesses and patients.
"You can see this is not about having a dispensary on every corner," Beshear said. "It is a limited program that we can monitor and fulfill the promise we made of doing this safely, but also having access in each region for people that do qualify."
The program can be expanded with more businesses in the future depending on demand and whether more qualifying medical conditions are added, which Beshear <a href="https://www.benzinga.com/markets/cannabis/24/01/36508539/kentucky-gov-beshear-wants-to-add-glaucoma-aids-and-13-more-conditions-to-medical-marijuana-prog">has promoted</a>.
"This is likely the minimum that you will see on the program moving forward. But again, you can always scale up. Scaling back hurts businesses, hurts people and hurts access," Beshear said. &#8220;We don't start huge. We start with a manageable program that, yes, can grow."
In March of this year, <a href="https://www.benzinga.com/markets/cannabis/23/03/31612072/kentucky-becomes-38th-state-to-legalize-medical-marijuana-as-gov-beshear-signs-bill-into-law" target="_blank" rel="noreferrer noopener">Kentucky became the 38th state</a> in the nation to legalize medical marijuana for patients with debilitating conditions.
Gov. Andy Beshear, government photo

Cannabis

Government

Regulations

Health Care

Legal

Kentucky Gov Beshear Announces Lottery To Award Medical Marijuana Licenses: 'A Chance For Everyone' Who Meet Criteria, Not Just Big Companies

Former Secretary of State Hillary Clinton recently expressed her views on a post from the Biden-Harris campaign, criticizing former President Donald Trump for his tax policies favoring the wealthy.
What Happened: On Thursday, Clinton responded to a post on X, formerly Twitter, from the Biden campaign that quoted Trump saying, &#8220;You're all people that have a lot of money. You're rich as hell. We're gonna give you tax cuts.&#8221; Clinton&#8217;s response was succinct: &#8220;If you&#8217;re a billionaire, he&#8217;s on your side. Otherwise, good luck.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If you&#39;re a billionaire, he&#39;s on your side. Otherwise, good luck. <a href="https://t.co/HzDrtTWLew">https://t.co/HzDrtTWLew</a>
&mdash; Hillary Clinton (@HillaryClinton) <a href="https://twitter.com/HillaryClinton/status/1780671379269902539?ref_src=twsrc%5Etfw">April 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
This isn&#8217;t the first time Clinton has criticized Trump&#8217;s policies. Earlier this month, she blamed him for the <a href="https://www.benzinga.com/news/24/04/38038951/hillary-clinton-blasts-trump-for-appointing-judges-that-overturned-legal-abortion-were-witnessing-th">fallout from the reversal</a> of Roe v. Wade, which she said is being felt across the nation.
See Also: <a href="https://www.benzinga.com/general/politics/24/04/38305131/elizabeth-warren-says-trump-had-only-2-accomplishments-as-president-huge-difference-between-bide?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elizabeth Warren Says Trump Had Only 2 Accomplishments As President: &#8216;Huge Difference Between&#8217; Biden, Trump</a>
Why It Matters: Clinton&#8217;s tweet comes in the wake of reports that Republican billionaires are <a href="https://www.benzinga.com/news/24/03/37838901/republican-billionaires-rally-to-fund-trumps-presidential-campaign-donors-extending-overwhelming-amo">rallying to fund Trump&#8217;s presidential campaign</a>. According to a Benzinga article, a high-dollar fundraiser was hosted in April to boost his campaign, signaling support from ultra-rich GOP figures.
Meanwhile, a recent poll showed President Joe Biden <a href="https://www.benzinga.com/news/24/04/38182671/biden-vs-trump-matchup-in-new-poll-shows-incumbents-lead-swelling-but-nearly-25-of-voters-dont-want">leading</a> Trump in a hypothetical matchup for the 2024 election. However, nearly 25% of voters indicated they don&#8217;t want either as President.
Read Next: <a href="https://www.benzinga.com/news/24/04/38305609/teary-biden-slams-trump-for-remarks-on-service-members-who-the-hell-does-he-think-he-is?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Teary Biden Slams Trump For Remarks On Service Members: &#8216;Who The Hell Does He Think He Is?&#8217;</a>

Hillary Clinton Says Trump Is On Your Side If You Are A Billionaire, 'Otherwise, Good Luck'

In response to the appearance of pro-Nazi content on Elon Musk&#8217;s social media platform, X, South Korea&#8217;s leading automaker&nbsp;Hyundai has decided to halt its advertising. This decision comes after a sponsored post from Hyundai was found next to anti-Semitic and pro-Nazi posts.
What Happened: The automaker confirmed that it had paused its advertising on X. The company also stated that it was addressing its concerns about brand safety with Musk&#8217;s company, <a href="https://www.nbcnews.com/tech/tech-news/hyundai-pauses-x-ads-nazi-content-platform-rcna148414">reported</a> NBC News.
"We have paused our ads on X and are speaking to X directly about brand safety to ensure this issue is addressed," Hyundai said in the statement.&nbsp;
A freelance journalist and X user, Nancy Levine Stearns, recently posted a screenshot of a Hyundai ad running on an X account that frequently posts Holocaust denial and anti-Semitism. The account in question has been suspended by X for violating its policy against abusive profiles.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">NEW: Hyundai Motor America spokesperson emailed me today about its ad on X appearing on a verified "Premium" account that posts pro-Hitler, antisemitic content: "We are immediately removing from the site. We are updating our parameters to avoid other instances similar to this." <a href="https://t.co/Y2oK8AVjCl">pic.twitter.com/Y2oK8AVjCl</a>
&mdash; Nancy Levine Stearns &#x270d;&#xFE0F; (@nancylevine) <a href="https://twitter.com/nancylevine/status/1780688883430330465?ref_src=twsrc%5Etfw">April 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Hyundai&#8217;s ad ran on the profile of a user who has defended Nazi leader Adolf Hitler and promoted anti-Semitic conspiracy theories. This account, which had a blue checkmark indicating it was a paid &#8220;Premium&#8221; subscriber, has been suspended by X.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38309306/legal-expert-says-tesla-shareholder-vote-to-approve-elon-musks-pay-for-his-past-wor?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Legal Expert Says Tesla Shareholder Vote To Approve Elon Musk&#8217;s Pay &#8216;For His Past Work&#8217; Is Like Setting &#8216;</a>
Despite the suspension, the account continued to post pro-Nazi content. X has been under fire for becoming a hub for pro-Nazi content under Musk&#8217;s ownership. This has led to a significant backlash from advertisers, with many major companies halting their advertising on the platform.
Hyundai did not immediately respond to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga</a>'s request for comment.
Why It Matters: This is not the first time that X has faced backlash over anti-Semitic content. In November, IBM <a href="https://www.benzinga.com/news/23/11/35842015/ibm-pulls-adverts-from-elon-musks-x-following-antisemitic-content-allegations">suspended its advertising</a> on X after its ads were found next to posts promoting Hitler and the Nazi Party. This led to a widespread advertiser backlash, with companies like Apple, Oracle, and Xfinity also having their ads displayed next to hateful content on the platform.
Following this, X faced a potential loss of up to $75 million in advertising revenue by the end of the year. This was due to major advertisers like Disney and Warner Bros. Discovery temporarily halting their advertising campaigns on X in response to <a href="https://www.benzinga.com/news/23/11/35949518/elon-musks-x-could-lose-75-million-in-ad-revenue-over-his-support-for-antisemitic-post-says-report">Musk&#8217;s endorsement of an anti-Semitic</a> post.
Despite the backlash, Musk <a href="https://www.benzinga.com/news/23/11/35860920/elon-musk-claps-back-as-apple-disney-ibm-pull-ads-from-x-over-his-support-for-antisemitic-content-i">stayed resilient</a>, stating that he was sticking to his principles after reports of several big companies pulling advertisements from X due to his posts supporting anti-Semitic conspiracy theories.
Read Next: <a href="https://www.benzinga.com/news/24/04/38288858/elon-musk-says-bring-it-on-after-russian-space-chief-touts-amur-rocket-says-it-can-be-reused-up-to-5?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Says &#8216;Bring It On&#8217; After Russian Space Chief Touts Amur Rocket, Says It Can Be Reused Up To 5X More Than SpaceX&#8217;s Falcon 9</a>
Image Via Shutterstock 
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Kaustubh Bagalkote</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/topic/kaustubh-bagalkote" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

Social Media

Elon Musk-Led X Suffers Setback After Hyundai Halts Ads On Platform Over Anti-Semitic Content

In a series of alleged retaliatory strikes, Israel reportedly targeted Iran, Syria, and Iraq. The strikes come in response to an Iranian missile attack on Israel.
What Happened: On Friday, Israel reportedly launched a missile strike on Iran, which was followed by explosions in central Iran, southern Syria, and the Baghdad area, as well as the Babil Governorate of Iraq, <a href="https://abcnews.go.com/International/live-updates/israel-gaza-hamas-war/?id=108860743">according</a> to ABC News.
Flight trackers showed that several flights bound for Iran had changed course, including flights from the United Arab Emirates.
Local sources in Syria reported that the airstrikes targeted sites belonging to the Syrian Army in the As-Suwayda and Daraa Governorates of southern Syria. Residents in Erbil and Mosul in Iraq also reported hearing the sounds of fighter jets.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">مراسل السويداء 24: أصوات قوية لتحليق طيران حربي في الريف الجنوبي لمحافظة <a href="https://twitter.com/hashtag/%D8%A7%D9%84%D8%B3%D9%88%D9%8A%D8%AF%D8%A7%D8%A1?src=hash&amp;ref_src=twsrc%5Etfw">#السويداء</a> جنوب <a href="https://twitter.com/hashtag/%D8%B3%D9%88%D8%B1%D9%8A%D8%A7?src=hash&amp;ref_src=twsrc%5Etfw">#سوريا</a>، سبقها بدقائق اصوات ثلاث انفجارات متتالية سمع دويها في مدينة السويداء والريف الغربي.. يتبع.. <a href="https://t.co/2bgRMFEpw7">pic.twitter.com/2bgRMFEpw7</a>
&mdash; السويداء 24 (@suwayda24) <a href="https://twitter.com/suwayda24/status/1781118124265230372?ref_src=twsrc%5Etfw">April 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/24/04/38286236/once-trumper-scaramucci-warns-re-electing-ex-president-would-result-in-american-fascism-and-be-very?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Once-Trumper&#8217; Scaramucci Warns Re-Electing Ex-President Would Result In &#8216;American Fascism&#8217; And Be &#8216;Very</a>
These strikes occurred following a drone and missile attack by Iran on Israel on Saturday night. The Iranian attack was allegedly in response to an Israeli airstrike that targeted a building next to the Iranian embassy in Damascus, resulting in the death of Mohammad Reza Zahedi, a senior IRGC commander in charge of Iran&#8217;s operations in Syria and Lebanon.
Why It Matters: The recent escalation of tensions between Israel and Iran has been a cause for concern. The Iranian missile and drone attack on Israel was seen as a significant shift in their conflict dynamics, potentially edging towards <a href="https://www.benzinga.com/news/24/04/38240360/what-a-full-blown-war-between-israel-and-iran-could-entail-according-to-one-report">full-scale war</a>.
The U.S. has also intensified <a href="https://www.benzinga.com/markets/asia/24/04/38316947/us-intensifies-economic-pressure-on-iran-in-response-to-attack-on-israel-we-will-continue-to-deploy">economic pressure on Iran</a> following the attack on Israel, imposing new sanctions on individuals and organizations involved in developing Iran's Unmanned Aerial Vehicle (UAV) capabilities.
Amid the escalating tensions, China has <a href="https://www.benzinga.com/news/24/04/38267600/amid-iran-israel-tensions-china-affirms-support-for-tehran-strengthens-ties">reiterated its support for Tehran</a>, strengthening its bilateral ties with Iran. 
Meanwhile, Israel's top leaders are reportedly <a href="https://www.benzinga.com/news/24/04/38264844/benjamin-netanyahus-war-cabinet-split-over-israels-war-strategy-amid-escalating-tensions-with-iran-r">in disagreement over the country's war strategy</a>, raising concerns about the potential impact on the Middle East's geopolitical stability.
Read Next: <a href="https://www.benzinga.com/news/24/04/38286407/gop-mega-donors-son-throws-support-behind-incumbent-president-in-biden-vs-trump-battle?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">GOP Mega Donor&#8217;s Son Throws Support Behind Incumbent President In Biden Vs. Trump Battle</a>
Image Via Shutterstock 
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Kaustubh Bagalkote</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/topic/kaustubh-bagalkote" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

Israel Reportedly Strikes Iran, Syria, Iraq In Retaliation For Missile, Drone Attack

Rep. Marjorie Taylor Greene (R-Ga.) has criticized House Speaker Mike Johnson (R-La.) for his alleged autocratic behavior and backroom dealings with Democrats. The tweet was posted on Tuesday.
What Happened: Greene, in her tweet, accused Mike Johnson of becoming a &#8220;mini tyrant.&#8221; She alleged that he was using underhanded tactics with Democrats to alter the rules of Congress, thereby maintaining his power and pushing through the agendas of President Joe Biden and Senate Majority Leader Chuck Schumer (D-N.Y.).
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Mike Johnson, the constitutional attorney, has turned into a mini tyrant. He's using backroom deals with Democrats to change the rules of Congress to continue clinging onto his power while passing Joe Biden and Chuck Schumer's wishlist. We need a new Speaker!! <a href="https://t.co/NhTwVJujQN">pic.twitter.com/NhTwVJujQN</a>
&mdash; Rep. Marjorie Taylor Greene&#x1f1fa;&#x1f1f8; (@RepMTG) <a href="https://twitter.com/RepMTG/status/1781013989331226919?ref_src=twsrc%5Etfw">April 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/24/04/38286407/gop-mega-donors-son-throws-support-behind-incumbent-president-in-biden-vs-trump-battle?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">GOP Mega Donor&#8217;s Son Throws Support Behind Incumbent President In Biden Vs. Trump Battle</a>
This tweet comes in the wake of Greene&#8217;s ongoing campaign to unseat Johnson, a campaign that has recently been joined by Rep. Thomas Massie (R-Ky.). Despite former President Donald Trump&#8217;s endorsement of Johnson, Greene has been pushing for a vote on Johnson&#8217;s removal, particularly over issues related to Ukraine aid.
Why It Matters: Johnson quashed rumors about considering changes to make his leadership more secure, despite pressure from Republican hard-liners who deemed it a &#8220;red line.&#8221; Johnson criticized the existing rule allowing easy ousting but affirmed it would remain, <a href="https://abcnews.go.com/Politics/mike-johnson-wont-change-rules-ousting-house-speakers/story?id=109395286">reported</a> ABC News.
He faced opposition from the party&#8217;s right flank, led by Greene, who demanded assurances he wouldn&#8217;t alter the rule. Amidst the standoff, Johnson navigated delicate balances between advancing national security bills and retaining his position, with some members threatening to oust him if he altered the threshold for a motion to vacate.
Johnson has been facing criticism from conservatives due to the lack of border security provisions in his latest foreign aid proposal. He <a href="https://www.benzinga.com/news/24/04/38305637/mike-johnson-on-border-criticism-some-of-my-colleagues-want-the-speaker-of-the-house-to-have-a-magic">dismissed the criticism</a>, attributing the lack of action to Senate and White House Democrats. He stated, "Some of my colleagues want the Speaker of the House to have a magic wand. If we could close the border ourselves, we would have done it a long time ago.&#8221;
Johnson&#8217;s comments came after the release of legislative text for three bills that would combine military assistance to Ukraine, Israel, and allies in the Indo-Pacific with humanitarian aid for Gaza. These bills, however, do not include a border security measure, a reversal from Johnson's previous indication that aid for Ukraine would be tied to such measures. This has been a point of contention for Greene and her supporters, as seen in her <a href="https://www.benzinga.com/news/24/04/38284071/marjorie-taylor-greene-bid-to-oust-speaker-mike-johnson-joined-by-thomas-massie-its-a-clusterf-k">recent efforts</a> to remove Johnson from his position as Speaker.
Read Next: <a href="https://www.benzinga.com/news/24/04/38308231/trumps-niece-says-ex-president-has-never-faced-constellation-of-horrors-hes-currently-experiencing-a?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Niece Says Ex-President Has Never Faced &#8216;Constellation Of Horrors He&#8217;s Currently Experiencing&#8217; Amid Stack Of Criminal Trials: &#8216;Not Going To Sit Well With Him&#8217;</a>
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Shivdeep Dhaliwal</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

Marjorie Taylor Greene Says Mike Johnson Has Turned Into A 'Mini Tyrant': 'We Need A New Speaker'

Journalist Justin Baragona shared a dismissed juror&#8217;s impression of former President Donald Trump during his ongoing trial on Thursday.
What Happened: On Thursday, Baragona tweeted a comment made by a dismissed juror about Trump&#8217;s appearance during his trial. The juror, in an <a href="https://www.msnbc.com/ana-cabrera-reports/watch/dismissed-juror-describes-seeing-trump-in-the-courtroom-during-hush-money-trial-209256005671">interview</a> with MSNBC&#8217;s Yasmin Vossoughian, noted a change in Trump&#8217;s complexion, stating: &#8220;You know, he looked less orange, definitely like more yellowish, like yellow.&#8221;
&#8220;He doesn&#8217;t look angry, he looks bored. He wants this finish and do his stuff.&#8221; The juror said other perspective jurors understood the gravity of the case and its historic nature.
The juror revealed that she became a citizen of the United States in August and this was her first ever time to have been called for jury duty.
The juror said she was dismissed because she said she couldn&#8217;t be impartial. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Dismissed Trump juror tells MSNBC of her impression of the ex-president: &quot;You know, he looked less orange, definitely like more yellowish, like yellow.&quot; <a href="https://t.co/q1DZyWaEX7">pic.twitter.com/q1DZyWaEX7</a>
&mdash; Justin Baragona (@justinbaragona) <a href="https://twitter.com/justinbaragona/status/1780978306814247175?ref_src=twsrc%5Etfw">April 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/24/04/38305609/teary-biden-slams-trump-for-remarks-on-service-members-who-the-hell-does-he-think-he-is?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Teary Biden Slams Trump For Remarks On Service Members: &#8216;Who The Hell Does He Think He Is?&#8217;</a>
The tweet comes amidst the high-profile trial involving Trump and alleged hush money payments. The jury, consisting of 7 men and 5 women, was selected after a lengthy process that involved questioning hundreds of potential jurors about their ability to remain impartial.
Why It Matters: The trial has garnered significant attention, not only for the charges against the former president but also for the composition of the jury. Among the 12 jurors, two are lawyers, a fact that Trump&#8217;s former attorney, Timothy Parlatore, described as &#8220;very unusual&#8221; in an <a href="https://www.benzinga.com/news/24/04/38305694/former-trump-attorney-says-very-unusual-to-have-lawyers-on-the-jury-they-can-be-a-very-strong-voice">interview</a> with CNN. He suggested that the presence of lawyers on the jury could be either advantageous or disadvantageous, depending on the specifics of the case.
The trial is a critical event for Trump Media &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>), as the outcome could significantly impact the company&#8217;s reputation and stock performance.
Read Next: <a href="https://www.benzinga.com/news/24/04/38285714/no-more-inventory-discounts-on-tesla-cars-as-ceo-elon-musk-says-sales-system-has-turned-complex-and?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">No More Inventory Discounts On Tesla Cars As CEO Elon Musk Says Sales System Has Turned &#8216;Complex And Inefficient&#8217;</a>
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Shivdeep Dhaliwal</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

Trump Looks Less Orange, More Yellow Says Dismissed Hush Money Trial Juror: 'He Doesn't Look Angry, He Looks Bored'

Owner of X, Elon Musk, has announced plans to fund a national signature campaign in support of the First Amendment, amid ongoing debates about free speech.
What Happened: On Thursday, Elon Musk took to X, formerly Twitter, to express his commitment to free speech. &#8220;Given the relentless attacks on free speech, I am going to fund a national signature campaign in support of the First Amendment,&#8221; he posted.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Given the relentless attacks on free speech, I am going to fund a national signature campaign in support of the First Amendment
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1781002178708082904?ref_src=twsrc%5Etfw">April 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38309306/legal-expert-says-tesla-shareholder-vote-to-approve-elon-musks-pay-for-his-past-wor?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Legal Expert Says Tesla Shareholder Vote To Approve Elon Musk&#8217;s Pay &#8216;For His Past Work&#8217; Is Like Setting &#8216;</a>
This announcement comes in the wake of Musk&#8217;s recent interactions on the subject of free speech. He had previously <a href="https://www.benzinga.com/news/24/04/38306161/elon-musk-reacts-to-npr-ceos-remarks-on-freedom-of-speech-super-powerful-ai-programmed-in-this-way-h">raised concerns</a> about the potential dangers of super-powerful artificial intelligence (AI) on social media platforms, warning of the &#8220;civilization-level risks&#8221; posed by such AI. 
Why It Matters: Musk&#8217;s commitment to free speech has been a topic of discussion in recent times. He had earlier filed a lawsuit against the Center for Countering Digital Hate (CCDH) for <a href="https://www.benzinga.com/general/social-media/24/03/37920503/elon-musk-whiffs-in-lawsuit-against-watchdog-group-judge-blasts-case-as-trying-to-punish-def">calling him out</a> for hate speech, which was later dismissed by a California judge. 
Furthermore, Musk has been vocal about his <a href="https://www.benzinga.com/news/24/04/38156008/elon-musk-fires-back-at-censorship-supporters-with-a-cryptic-post-youre-not-woke-or-progressive-your">stance on censorship</a>, criticizing those who support it. His recent tweet further solidifies his position as a staunch supporter of free speech. 
Photo Courtesy: Shutterstock.com
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38306270/dogecoin-could-make-elon-musks-fate-loves-irony-comment-come-true-if-it-flips-ethereums-ma?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dogecoin Could Make Elon Musk&#8217;s &#8216;Fate Loves Irony&#8217; Comment Come True If It Flips Ethereum&#8217;s Market Cap At Last Bull Run, Says This Crypto Influencer</a>
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Shivdeep Dhaliwal</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

Tech

Elon Musk Announces Intent To Finance 'National Signature Campaign' In Support Of First Amendment, Alleging 'Relentless Attacks On Free Speech

Crypto analyst Michaël van de Poppe has suggested that Bitcoin&#8216;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price may soon experience a significant rebound, despite the waning hype surrounding the upcoming halving event.
What Happened: Van de Poppe took to X on Thursday to share his prediction. He noted that the current market conditions could pave the way for a price surge in the near future. 
He wrote, &#8220;Pretty significant chance #Bitcoin will be bouncing from this area upwards for some relief. The hype is slowly fading away for Bitcoin as the halving is approaching and narratives will change.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Pretty significant chance <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> will be bouncing from this area upwards for some relief. The hype is slowly fading away for Bitcoin as the halving is approaching and narratives will change. <a href="https://t.co/D3JWVihXID">pic.twitter.com/D3JWVihXID</a>
&mdash; Michaël van de Poppe (@CryptoMichNL) <a href="https://twitter.com/CryptoMichNL/status/1781000487480758385?ref_src=twsrc%5Etfw">April 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Van de Poppe&#8217;s forecast comes amid a period of market stabilization. Despite recent volatility, Bitcoin and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) have both <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38312737/bitcoin-defies-165m-etf-outflows-bounces-above-62-000">managed to bounce back</a> above the $62,000 and $3,000 marks, respectively.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38299089/trump-related-maga-memecoin-onboards-roger-stone-as-partner?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump-Related MAGA Memecoin Onboards Roger Stone As Partner</a>
Additionally, the highly anticipated Bitcoin halving is just two days away, and analysts at 10x Research have suggested that the <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38321951/what-happens-after-the-bitcoin-halving">post-halving scenario</a> may not necessarily mirror the pre-halving frenzy.
Why It Matters: The Bitcoin halving event, which occurs approximately every four years, is a significant milestone for the cryptocurrency. The event involves a 50% reduction in the rewards miners receive for validating transactions, ultimately impacting the supply of new Bitcoins entering the market. 
Historically, halving events have been associated with significant price movements in Bitcoin, making them a focal point for investors and analysts.
Despite the recent market volatility, some industry experts remain bullish on Bitcoin&#8217;s long-term prospects. Anthony Scaramucci, the founder of SkyBridge Capital, <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38321903/bitcoin-to-200k-after-halving-skybridges-scaramucci-believes-the-crypto-will-eclipse-gold-">recently suggested</a> that Bitcoin could reach $200,000 per coin following the halving, while a Fidelity director <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38320609/holding-0-001-bitcoin-could-make-you-a-multimillionaire-according-to-fidelity-director">highlighted</a> the potential for even a small investment in Bitcoin to create generational wealth.
Price Action: According to data <a href="https://pro.benzinga.com/dashboard">from Benzinga Pro</a>, Bitcoin is presently trading at $63,103, representing a decrease of 0.65% over the last 24 hours. However, it has surged by 42.86% since the beginning of the year.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38284502/dogecoin-killer-shiba-inu-sees-significant-increase-in-token-burn-rate-as-price-recovers-i?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Dogecoin Killer&#8217; Shiba Inu Sees Significant Increase In Token Burn Rate, As Price Recovers — Is A Turnaround In The Making?</a>
Image Via Shutterstock 
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Kaustubh Bagalkote</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/topic/kaustubh-bagalkote" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Bitcoin Analyst Predicts 'Significant Chance' Of Price Bounce Amid Fading Hype: 'Narratives Will Change'

The latest development in the legal battles surrounding former U.S. President Donald Trump has seen his bid to delay several lawsuits linked to the Capitol attack denied. This decision was reportedly made by U.S. District Judge Amit Mehta in Washington.
What Happened: On Thursday, Trump&#8217;s defense lawyers&#8217; plea to postpone the civil cases while he fights the 2020 election interference criminal case was dismissed. These cases, filed by Democratic lawmakers and police officers, allege harm suffered during the Capitol attack on January 6, 2021, and accuse Trump of inciting the riot, <a href="https://www.chicagotribune.com/2024/04/18/trump-jan-6-lawsuits-delay-request/">reported</a> the Chicago Tribune.
Trump&#8217;s defense argued that his speech prior to the attack was a matter of public concern and within the scope of presidential immunity. However, this claim was rejected by Washington&#8217;s federal appeals court in December, allowing the lawsuits to proceed.
See Also: <a href="https://www.benzinga.com/news/24/04/38270988/elon-musk-reacts-after-trump-posts-screenshot-of-tesla-ceos-post-about-lawfare-not-being-applied-equ?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts After Trump Posts Screenshot Of Tesla CEO&#8217;s Post About &#8216;Lawfare:&#8217; &#8216;Not Being Applied Equally To Joe And Hunter Biden&#8217;</a>
Judge Mehta, an appointee of former President Barack Obama, stated that the public interest lies in the swift resolution of these civil lawsuits, alongside the criminal case. He added that safeguards can be put in place to allow the lawsuits to advance without infringing on Trump&#8217;s Fifth Amendment rights.
Why It Matters: This decision comes amidst a series of legal challenges for the former president. In August 2023, Trump refused to <a href="https://www.benzinga.com/news/23/08/33806596/trump-refuses-to-pledge-compliance-with-judges-order-in-jan-6-case-the-whole-thing-is-a-fake">pledge compliance</a> with a judge&#8217;s order in the Jan. 6 case, calling it a &#8220;fake.&#8221;
Furthermore, Trump is also facing a criminal trial involving alleged hush money payments. The jury for this trial was <a href="https://www.benzinga.com/general/politics/24/04/38326553/trump-hush-money-trial-has-12-jurors-here-are-the-7-men-5-women-to-decide-former-presidents-fate">selected</a> on Thursday, marking another step towards the commencement of the trial.
Read Next: <a href="https://www.benzinga.com/news/24/04/38263998/trumps-niece-says-ex-presidents-mandatory-courtroom-presence-will-give-jury-front-row-seat-of-his-ba?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Niece Says Ex-President&#8217;s Mandatory Courtroom Presence Will Give Jury Front-Row Seat Of His Bad Behavior: &#8216;Donald Is Finally Confronting His Criminal Charges&#8217;</a>
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Shivdeep Dhaliwal</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

Trump's Bid To Pause Jan.6 Capitol Riot Case Denied By Judge

The <a href="https://www.benzinga.com/topic/hemp">hemp </a>market, after riding the highs of the &#8220;green rush&#8221; in 2021, faced significant challenges in 2022, similar to the broader global cannabis market downturn. This period was marked by considerable corrections in cultivation and prices. However, a recent report from the U.S. Department of Agriculture (USDA) brings promising news: the market is showing signs of stabilization.
<h3 class="wp-block-heading">Key Insights From USDA Report</h3>
The USDA&#8217;s National Agricultural Statistics Service released a <a href="https://release.nass.usda.gov/reports/hempan24.pdf">report </a>indicating positive trends in the hemp industry:
Market Value and Acreage: The value of open hemp production rose to $291 million, an 18% increase from the previous year, with a stable cultivation area of around 27,000 acres nationwide. The report highlighted that the unprotected segment of the hemp market (areas not covered by specific hemp programs) reached a production value of $258 million.
Yield Improvements: Interviews with farmers revealed that increased market value is partly due to improved yields in various hemp categories, including grain, fiber and floral hemp. The report, now in its third consecutive year, aims to standardize agricultural research and focuses on CBD and non-intoxicating cannabis crops, designated as &#8220;specialty crops&#8221; since the 2018 Farm Bill.
<ul>
<li>Fiber hemp yield for 2023 was estimated at 4,053 pounds per acre, a significant increase from the previous year.</li>
<li>Floral hemp yield was estimated at 1,088 pounds per acre, also showing an improvement.</li>
<li>Grain hemp yield was estimated at 779 pounds per acre, marking a notable increase.</li>
</ul>
Leading States: South Dakota (3200 harvested area), Montana (2300), Oregon (2900), and California (2100) emerged as the top hemp-producing states, collectively accounting for nearly half of the country&#8217;s hemp cultivation area.
Prices: For various categories of industrial floral hemp prices were recorded as follows: 
<ul>
<li>Dried flower at $4.38 per pound, bucked at $6.35, hand-trimmed at $87.8, and $59.2 for other forms. </li>
<li>Notably, there has been a decrease in the price of dried flowers, which stood at $11.90 per pound in 2022. </li>
<li>However, the price for bucked hemp experienced a significant increase, doubling from the previous year&#8217;s $3.12.</li>
</ul>
The process of bucking, which is an industrial method used to separate cannabinoid-rich flowers from the rest of the biomass, highlights the differentiated pricing based on the processing level of hemp.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">In 2023, the value of hemp production in the open and under protection for the United States totaled $291 million, up 18% from 2022. See more <a href="https://twitter.com/hashtag/AgStats?src=hash&amp;ref_src=twsrc%5Etfw">#AgStats</a> in the National Hemp Report &#x27a1;&#xFE0F;<a href="https://t.co/xeuwXqTpDB">https://t.co/xeuwXqTpDB</a>
&mdash; National Agricultural Statistics Service (@usda_nass) <a href="https://twitter.com/usda_nass/status/1780673275707728216?ref_src=twsrc%5Etfw">April 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h3 class="wp-block-heading">Why Hemp Matters</h3>
Hemp is gaining attention for its <a href="https://www.benzinga.com/markets/cannabis/23/06/32783960/hemp-could-be-the-biggest-investment-opportunity-since-plastic">environmental benefits and versatility</a>. As a gluten-free crop with a great nutritional profile, Hemp offers a sustainable alternative in food, fiber, and construction material production. It requires <a href="https://www.benzinga.com/markets/cannabis/24/01/36539826/is-eco-friendly-hemp-farming-profitable-this-company-proves-it-is-and-now-leads-a-revolution-in-">fewer pesticides and less water </a>than cotton and is twice as efficient as trees in carbon absorption, positioning hemp as a crucial crop for environmental sustainability.
This USDA report underscores the hemp market&#8217;s resilience and <a href="https://www.benzinga.com/general/biotech/24/03/37633391/usda-invests-10m-in-hemp-research-tribal-lands-and-bidens-hemp-biotech-initiative">potential for growth</a>, highlighting the industry&#8217;s adaptation to challenges and its role in sustainable agriculture.

USDA Hemp Market Report Shows Stability And Growth Amid Challenges

GSUN

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

The 12 jurors who will decide the fate of former President Donald Trump were selected in the highly anticipated criminal trial involving alleged <a href="https://www.benzinga.com/general/politics/24/04/38251447/trump-hush-money-trial-preview-key-witnesses-2024-campaign-impact-prison-time-trump-could-face-i">hush money payments.</a>
Here are the latest details and what comes next.
What Happened: A lengthy process that saw <a href="https://www.benzinga.com/general/social-media/24/04/38282616/trump-trial-gets-7-jurors-11-to-go-their-old-social-media-posts-take-center-stage-in-court-e">hundreds of potential jurors</a> asked about their necessity to be impartial in the trial against Trump is one step closer to the trial beginning.
On Thursday, jurors seated for the hush money case now stands at 12, the total needed for the verdict, as <a href="https://www.nbcnews.com/politics/donald-trump/live-blog/trump-hush-money-trial-day-3-live-updates-rcna145936">shared </a>by NBC News.
Making up the jury are seven men and five women. Here are the jurors and their professions, as <a href="https://www.nbcnews.com/politics/donald-trump/meet-the-first-7-jury-members-as-trumps-hush-money-trial-progresses-rcna148198">reported </a>by NBC News. 
<ol>
<li>Male, works in sales</li>
<li>Male, investment banking</li>
<li>Male, attorney</li>
<li>Male, security engineer</li>
<li>Female, teacher</li>
<li>Female, software engineer</li>
<li>Male, attorney, likes the outdoors</li>
<li>Male, retired, previously worked in wealth management</li>
<li>Female, speech therapist</li>
<li>Male, commerce worker</li>
<li>Female, product development manager</li>
<li>Female, physical therapist</li>
</ol>
"We have our jury," Judge Juan Merchan said after a 12th juror was agreed upon by the prosecution and defense.
Merchan gave instructions to the jurors Thursday before they left, reminding them that they cannot discuss the case. The judge reminded the jurors that they are expected to view the case with a "fair and impartial manner."
Getting to 12 jurors Thursday could come as a surprise after the way the court day began. After reaching seven jurors Tuesday before adjourning the trial until Thursday, two of the jurors were removed early Thursday.
One juror was dismissed after a prior arrest was brought into question.
Juror 2, an oncology nurse, was excused earlier in the day after saying that after sleeping on the case, she worried she could no longer be impartial. She also was concerned about her identity becoming public with family already asking if she was on the jury.
The jury selection process has also seen large numbers of potential jurors dismissed after saying they can't be impartial in the case. When Merchan asked a pool of 96 potential jurors to raise their hand if they can't be impartial in the case, 48 were immediately dismissed.
Related Link: <a href="https://www.benzinga.com/general/politics/24/04/38261008/donald-trump-argues-political-prosecution-before-jury-selection-in-new-york-trial-judge-not-goin">Donald Trump Argues &#8216;Political Prosecution&#8217; Before Jury Selection In New York Trial: &#8216;Judge Not Going To Allow Me To Escape This Scam&#8217;</a>
What's Next: Six additional jurors are still needed, who will serve as alternates.
The plan, as of now, is for the trial to begin Monday. This could happen if the alternates are selected on Friday. "I'm hopeful we will finish tomorrow," Merchan said.
Trump's hush money criminal trial is expected to last six to eight weeks.
Speaking to reporters after the case wrapped Thursday, Trump said he should have been campaigning in key states for the 2024 election.
"I've been here all day," Trump said.
Trump called the case an "unfair trial."
"The whole thing is a mess."
DJT Price Action: Shares of Trump Media &amp; Technology Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) have been volatile during Trump's legal proceedings.
Shares spiked Thursday, but it was likely unrelated to the case. The<a href="https://www.benzinga.com/markets/equities/24/04/38319481/why-trump-media-technology-group-shares-are-gaining-thursday"> shares traded higher </a>after a filing from the company explained to shareholders how to keep the shares they own from being loaned out for short selling.
DJT shares closed Thursday up 25.72% to $33.19 versus a 52-week trading range of $22.55 to $79.38.
Read Next: <a href="https://www.benzinga.com/general/politics/24/04/38279176/trump-hush-money-trial-draws-reaction-from-congressman-talk-show-hosts-worse-than-anything-richa">Trump Hush Money Trial Draws Reaction From Congressman, Talk Show Hosts: &#8216;Worse Than Anything Richard Nixon Ever Did&#8217;</a>
Photo: Created with artificial intelligence on MidJourney and Zolnierek on Shutterstock

Trump Hush Money Trial Has 12 Jurors: Here Are The 7 Men, 5 Women To Decide Former President's Fate

Two of the greatest and most well-known movie directors of the past 50 years are teaming up on a new series. Here's what Martin Scorsese and Steven Spielberg are up to and how it could help<a href="https://www.benzinga.com/topic/streaming-stocks"> a streaming company.</a>
What Happened: Scorsese and Spielberg are uniting to serve as executive producers on a "Cape Fear" series. The series, which is based on 1962 and 1991 films will <a href="https://www.benzinga.com/topic/apple-tv-0">stream on AppleTV+</a>, a unit of Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>). 
It is unknown if Scorsese or Spielberg will direct or write the series, or both will simply serve as producers on the project. The news was reported by <a href="https://variety.com/2024/film/news/martin-scorsese-frank-sinatra-biopic-dicaprio-jennifer-lawrence-1235973769/">Variety</a>. 
Starring Nick Nolte and Robert De Niro, the 1991 film grossed $79.1 million domestically and $182.3 million worldwide. The film centers on a lawyer who is stalked by a former client who is released from prison. Scorsese was the director of the film.
The 1962 film starred Gregory Peck and Robert Mitchum. &nbsp;
The new series isn't the only item in the works for Scorsese or Spielberg.
Scorsese plans on shooting back-to-back films according to Variety. One would be about Jesus and the other about musician Frank Sinatra.
The Jesus film is based on the 1973 book "Life of Jesus" and Scorsese is considering independently financing it.
The Sinatra film is eying Leonardo DiCaprio as the singer and Jennifer Lawrence to play the singer's second wife, Ava Gardner. This film is drawing attention from several companies including Apple, but Sony Group Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) is believed to be in the lead.
Spielberg is also working on a UFO film and on a series based on Napoleon Bonaparte. The series, which sources material from an unfinished film of Stanley Kubrick, will air on Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)-owned HBO.
Related Link: <a href="https://www.benzinga.com/general/entertainment/24/04/38024244/appletv-a-streaming-winner-new-survey-shows-platform-has-smallest-library-highest-rated-con">AppleTV+ A Streaming Winner? New Survey Shows Platform Has Smallest Library, Highest Rated Content</a>
Why It's Important: Even as producers of the new series and no involvement beyond that, the inclusion of Scorsese and Spielberg could help AppleTV+ have a new hit series that will get a lot of attention.
Given the previous source material and the names attached, it could be one of the most highly anticipated series for Apple as it nears.
Apple <a href="https://www.benzinga.com/24/03/37558754/apples-1b-gamble-on-3-blockbusters-analyzing-box-office-results-streaming-impact-and-oscar-nominatio">spent around $1 billion</a> on three blockbuster movies in 2023, with one being the Scorsese picture "Killers of the Flower Moon."
The film drew critical praise and was nominated for 10 Academy Awards, but was ultimately shut out. The film also grossed $67.9 million domestically and $156.9 million worldwide.
Apple has worked with Spielberg in the past as the film legend is a <a href="https://www.benzinga.com/general/entertainment/23/11/35717790/tom-hanks-steven-spielberg-back-together-for-world-war-ii-series-on-appletv-here-are-the-de">producer alongside</a> Tom Hanks on "Masters of the Air."
While it has a smaller content library, Apple's willingness to spend and grab big names along with key sports rights could make its streaming platform a must-subscribe for consumers.
Read Next: <a href="https://www.benzinga.com/general/entertainment/23/10/35430485/apple-hikes-subscription-prices-for-tv-arcade-bundle-will-also-get-more-expensive">Apple Hikes Subscription Prices For TV+, Arcade — Bundle Will Also Get More Expensive</a>
Photo: Steven Spielberg and Martin Scorsese in the press room at the 66th Annual Golden Globe Awards, photo by <a href="https://www.shutterstock.com/g/sbukley">s_bukley</a> via Shutterstock

Entertainment

AAPL

Sony Group Corporation American Depositary Shares

SONY

Steven Spielberg, Martin Scorsese Team Up On New Series For This Streaming Platform

Amid the dynamic biotech landscape, the sector is set to witness an upward trajectory fueled by consistent advancements. Therefore, it could be wise to buy fundamentally strong biotech stocks Protalix BioTherapeutics (PLX), Organogenesis Holdings (ORGO), and ANI Pharmaceuticals (ANIP) for monthly gains. Read more... The biotechnology sector has been at the forefront of innovation. Over the past five years, the biotech industry grew at a CAGR of 7%, and by 2025, the biotech industry is expected to reach a <a href="https://www.nasdaq.com/articles/3-biotech-stocks-with-promising-pipelines-and-big-growth-potential-in-2024">valuation of $725 billion</a>.
Given the industry's steady growth prospects, investors could buy biotech stocks Protalix BioTherapeutics, Inc. (<a href="https://stocknews.com/stock/PLX/">PLX</a>), Organogenesis Holdings Inc. (<a href="https://stocknews.com/stock/ORGO/">ORGO</a>), and  ANI Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ANIP/">ANIP</a>) for monthly gains.
The growing foothold of personalized medicine and an increasing number of orphan drug formulations are opening new avenues for biotechnology applications and are driving the influx of emerging and innovative biotechnology companies, further boosting market revenue.
The global biotechnology market is expected to grow at a <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">CAGR of 14%</a> until 2030.
According to a new report titled Global Use of Medicines 2023, the total spending and global demand for medicines will increase over the next five years to <a href="https://www.iqvia.com/newsroom/2023/01/global-market-for-medicines-to-rise-to-19-trillion-by-2027-says-report-from-iqvia-institute">approximately $1.9 trillion</a> by 2027. The underlying growth rate of 3-6% in spending will be driven by new drug launches and broader use of recently launched brands despite efforts by payers to constrain their budgets and the impact of lower-cost options.
With these favourable trends in mind, let's delve into the fundamentals of the three best <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, beginning with the third choice.
Stock #3: Protalix BioTherapeutics, Inc. (<a href="https://stocknews.com/stock/PLX/">PLX</a>)
PLX is a biopharmaceutical company that engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
PLX's trailing-12-month asset turnover ratio of 0.88x is 125.2% higher than the industry average of 0.39x, while its trailing-12-month EBITDA margin of 23.16% is 358.1% higher than the industry average of 5.06%.
For the nine months that ended September 30, 2023, PLX's total revenue stood at $55.01 million, up 41% year-over-year. Its operating income came to $16.08 million, compared to an operating loss of $10.52 million in the year-ago period.
For the same period, its balance of cash and cash equivalents at end of period increased 90.4% from the prior-year period to $20.41 million. As of September 30, 2023, PLX's total current assets stood at $72.62 million, compared to $44.88 million as of December 31, 2022.
Street expects revenue to be $62.15 million for the fiscal year ending December 2024. Its EPS is expected to grow at 38.1% year-over-year to $0.15 for the same year. The company surpassed consensus revenue and EPS estimates in each of the trailing four quarters.
The stock has declined 5.7% over the past year to close the last trading session at $1.49.
PLX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its promising outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
It has an A grade for Value. It is ranked #30 in the 349-stock <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
Beyond what is stated above, we've also rated PLX for Momentum, Growth, Quality, Stability and Sentiment. Get all PLX ratings <a href="https://stocknews.com/stock/PLX/">here</a>.
Stock #2: Organogenesis Holdings Inc. (<a href="https://stocknews.com/stock/ORGO/">ORGO</a>)
ORGO develops, manufactures, and markets solutions for advanced wound care, surgical, and sports medicine sectors. Its clientele includes hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices, served through adept direct sales representatives and independent agencies.
The stock's trailing-12-month gross profit margin of 76.43% is 33.9% higher than the industry average of 57.08%. Its EBITDA margin of 8.11% is 60.5% higher than the 5.06% industry average.
For the fiscal 2023 third quarter that ended September 30, 2023, ORGO's income from operations rose 352.5% year-over-year to $8.05 million. Its <a href="https://www.investopedia.com/terms/a/adjusted-ebitda.asp">adjusted EBITDA</a> grew 37.6% from the year-ago value to $15.97 million. Additionally, the company's adjusted net income increased 4.1% from the prior year's quarter to $5.30 million, while net income per share stood at $0.02.
The consensus revenue estimate of $457.07 million for the fiscal year ending December 2024 indicates a 3.8% year-over-year rise. Likewise, the consensus EPS estimate of $0.05 for the ongoing year period is estimated to grow 25% from the prior year. Moreover, the company surpassed the consensus EPS estimates in three of four trailing quarters.
Shares of ORGO have gained 70.2% over the past nine months to close the last trading session at $3.49.
It's no surprise that ORGO has an overall rating of B, which equates to Buy in our proprietary rating system.
ORGO has an A grade for Value and a B in Quality. It is ranked #26 in the same industry.
In addition to the POWR Ratings highlighted above, one can access ORGO's ratings for Stability, Sentiment, Momentum, and Growth <a href="https://stocknews.com/stock/ORGO/">here</a>.
Stock #1: ANI Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ANIP/">ANIP</a>)
ANIP develops, manufactures, and markets both branded and generic prescription pharmaceuticals. It specializes in controlled substances, oncology products, hormones, steroids, injectables, and various formulations, such as extended-release and combination products.
On January 23, ANIP unveiled the launch of Pentoxifylline Extended-Release (ER) Tablets, the generic counterpart to the Reference Listed Drug (RLD) Trental. Valued at around $19.7 million annually as per IQVIA/IMS Health estimates, the launch positions ANIP to sustain its generics business success in a moderately competitive market.
For the fiscal 2023 third quarter that ended September 30, 2023, ANIP's net revenues increased 57.3% year-over-year to $131.83 million. Its adjusted EBITDA grew 98.3% from the year-ago value to $36.48 million. Additionally, adjusted net income available to common shareholders and adjusted earnings per share grew 155.3% and 119% from the prior year's period to $24.27 million and $1.27, respectively.
Analysts expect revenue to increase 50.9% year-over-year to $477.25 million for the fiscal year that ended December 2023. Likewise, the EPS is estimated to grow 227.9% from the prior year to $4.46. Moreover, the company topped the consensus revenue and EPS estimates in all four trailing quarters.
Shares of ANIP have gained 43.7% over the past nine months, closing the last trading session at $54.20.
ANIP's strong fundamentals are reflected in its POWR Ratings. It has an overall rating of B, which equates to Buy in our proprietary rating system.
ANIP has an A grade for Growth and Sentiment and a B in Value. It is ranked #25 in the same industry.
<a href="https://stocknews.com/stock/ANIP/">Click here</a> to access the additional ANIP ratings (Momentum, Quality, and Stability).
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
PLX shares rose $0.11 (+7.38%) in premarket trading Wednesday. Year-to-date, PLX has declined -16.29%, versus a 3.28% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Nidhi Agarwal</h2> <img src='https:/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg' style="float:left; padding:5px;width:125px;">Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program.

Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities.<a href="https://stocknews.com/authors/?author=nidhi-agarwal">More...</a>The post <a href=https://stocknews.com/news/plx-orgo-anip-biotech-stock-success-top-3-picks-for-monthly-gains/>Biotech Stock Success: Top 3 Picks for Monthly Gains</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Biotech Stock Success: Top 3 Picks for Monthly Gains

The market has been high on Organogenesis Holdings Inc (ORGO)  stock recently. ORGO gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Organogenesis Holdings Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ORGO!See Full ORGO ReportWhat is Stock S

Should You Buy Organogenesis Holdings Inc (ORGO) Stock After it Is Higher By 5.45% in a Week?

Cantor starts Organogenesis at overweight, cites differentiated portfolio

Organogenesis Holdings Q4 2023 Earnings Preview

Organogenesis Holdings GAAP EPS of $0.00 in-line, revenue of $99.7M misses by $9.35M

Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript

Analyst Ryan Zimmerman of BTIG maintained a Buy rating on Organogenesis Holdings (ORGO – Research Report), with a price target of $6.00. Ryan Zimme...

Organogenesis Holdings: A Buy Rating with Anticipated Turnaround and Growth Prospects

Organogenesis Holdings Inc (ORGO) said after close Thursday that it earned $0.01 per share in quarter four 2023. The company reported earnings on an adjusted basis, so it may not be directly comparable to analyst estimates or prior periods.On the revenue line, the company reported $99.7 million, missing estimates by $9.4 m

Organogenesis Holdings Inc Down 24.09% To $2.71 After Earnings Meet

Buy Rating Affirmed for Organogenesis Holdings Amid Stable Product Pricing and Positive Market Dynamics

The biotech industry's growth prospects look promising due to advanced technologies like AI, the growing popularity of tailored treatments, a rise in chronic diseases, and higher R&D spending. Let's analyze the investment prospects of biotech stocks Innoviva (INVA), Organogenesis Holdings (ORGO), and Compugen (CGEN). Read more... The biotech industry is set for solid growth thanks to continuous innovations and the increasing need for advanced healthcare solutions, innovative vaccines, and therapies. Moreover, investments in research and development (R&amp;D), an aging population, rising demand for personalized medicines, and government initiatives bolster the sector's outlook.
Amid this favorable backdrop, investors could consider buying fundamentally strong biotech stocks: Innoviva, Inc. (<a href="https://stocknews.com/stock/INVA/">INVA</a>), Organogenesis Holdings Inc. (<a href="https://stocknews.com/stock/ORGO/">ORGO</a>), and Compugen Ltd. (<a href="https://stocknews.com/stock/CGEN/">CGEN</a>).
The biotech industry is booming worldwide thanks to significant advancements in drug development, such as targeted therapies and the application of genetic engineering. Increased investments in R&amp;D and a rise in clinical trials will likely boost the industry's prospects. The global biotechnology market is projected to reach $3.88 trillion by 2030, with a <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">CAGR of 14%</a>.
Meanwhile, the advances in AI and machine learning are helping bring innovation to the biotech industry. These technologies help with drug development and streamline manufacturing processes, contributing to the industry's growth. The global AI for Pharma and Biotech market is expected to reach $4.20 billion by 2027, growing at a <a href="https://www.linkedin.com/pulse/ai-pharma-biotech-market-size-2024-growth-u229e/">30.5% CAGR</a>.
Considering these conducive trends, let's analyze the fundamental aspects of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> picks, beginning with the third choice.
Stock #3: Innoviva, Inc. (<a href="https://stocknews.com/stock/INVA/">INVA</a>)
INVA engages in developing and commercializing pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA.
In terms of the trailing-12-month gross profit margin, INVA's 84.09% is 48% higher than the 56.84% industry average. Likewise, its 45.43% trailing-12-month <a href="https://www.investopedia.com/terms/e/ebit.asp">EBIT</a> margin is significantly higher than the 0.80% industry average. Additionally, its 38.85% trailing-12-month levered FCF margin is substantially higher than the 0.65% industry average.
INVA's total revenue for the fourth quarter that ended December 31, 2023, rose 30.4% to $85.84 million. The company's net product sales rose 34.9% over the prior-year quarter to $19.68 million.
In addition, its net income attributable to INVA's stockholders and net income per share came in at $61.53 million and $0.76, respectively, compared to a net loss and net loss per share of $68.31 million and $0.98, respectively, in the year-ago quarter.
Analysts expect INVA's EPS for the quarter ending June 30, 2024, to increase considerably year-over-year to $0.22. Its revenue for the quarter ending September 30, 2024, is expected to grow 8.7% year-over-year to $73.14 million. Over the past year, INVA's stock has gained 25% to close the last trading session at $14.63.
INVA's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect solid prospects. It has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It is ranked #29 out of 360 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. It has an A grade for Value and a B for Quality. <a href="https://stocknews.com/stock/INVA/">Click here</a> to see INVA's Growth, Momentum, Stability, and Sentiment ratings.
Stock #2: Organogenesis Holdings Inc. (<a href="https://stocknews.com/stock/ORGO/">ORGO</a>)
ORGO is a regenerative medicine company that develops, manufactures, and commercializes solutions for the advanced wound care, surgical, and sports medicine markets in the United States.
In terms of the trailing-12-month EBITDA margin, ORGO's 7.32% is 41.2% higher than the 5.18% industry average. Likewise, its 75.42% trailing-12-month gross profit margin is 32.7% higher than the 56.84% industry average. Also, its 0.95x trailing-12-month asset turnover ratio is 140.3% higher than the 0.40x industry average.
For the fiscal year that ended December 31, 2023, ORGO's net revenue came in at $433.14 million. Its gross profit was $326.66 million. The company's adjusted net income stood at $12.68 million, while its net income per share came in at $0.04. Additionally, as of December 31, 2023, its total assets amounted to $460.03 million, compared to $449.36 million as of December 31, 2022.
Analysts expect ORGO's revenue for the quarter ending September 30, 2024, to increase 6.8% year-over-year to $115.90 million. Over the past year, the stock has gained 39.8% to close the last trading session at $2.88.
ORGO's POWR Ratings reflect solid prospects. It has an overall rating of B, which translates to a Buy in our proprietary rating system.
It is ranked #27 out of 360 stocks in the same industry. It has an A grade for Value. <a href="https://stocknews.com/stock/ORGO/">Click here</a> to see ORGO's Growth, Momentum, Stability, Sentiment, and Quality ratings.
Stock #1: Compugen Ltd. (<a href="https://stocknews.com/stock/CGEN/">CGEN</a>)
CGEN is a clinical-stage therapeutic discovery and development company that researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe.
On January 8, 2024, CGEN announced that it is entitled to receive a $10 million milestone payment from AstraZeneca after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig, a PD-1/TIGIT bispecific antibody derived from CGEN's anti-TIGIT antibody.
In terms of the trailing-12-month gross profit margin, CGEN's 94.01% is 65.4% higher than the 56.84% industry average.
For the fiscal fourth quarter ended December 31, 2023, CGEN's revenue increased 346.1% year-over-year to $33.46 million. Its gross profit came in at $31.46 million, up 382.1% over the prior-year quarter.
Additionally, the company's net income and net income per share stood at $9.71 million and $0.11, respectively, compared to the previous year's net loss and net loss per share of $3.09 million and $0.04.
Street expects CGEN's revenue for the fiscal year ending December 31, 2024, to increase 13.3% year-over-year to $37.90 million. It surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, the stock has declined 261.3% to close the last trading session at $2.13.
It's no surprise that CGEN has an overall rating of B, which translates to a Buy in our proprietary rating system.
It has a B grade for Value and Sentiment. Within the Biotech industry, it is ranked #26. Beyond what we stated above, we also have given CGEN grades for Growth, Momentum, Stability, and Quality. Get all the CGEN ratings <a href="https://stocknews.com/stock/CGEN/">here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
INVA shares were trading at $14.54 per share on Monday morning, down $0.09 (-0.62%). Year-to-date, INVA has declined -9.35%, versus a 8.07% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/inva-orgo-cgen-3-biotech-stocks-with-potential-gains-watch-or-buy/>3 Biotech Stocks with Potential Gains - Watch or Buy?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks with Potential Gains - Watch or Buy?

ANIP

CGEN

INVA

HippoFi (OTC:ORHB) Hires World's Top Regenerative Therapy Expert Dr. Gail Naughton to Drive Commercialization Plans of its Proprietary Technologies

Press Releases

HippoFi Hires World's Top Regenerative Therapy Expert, Dr. Gail Naughton, to Drive Commercialization Plans of its Proprietary Technologies

ORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Organogenesis Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024

Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Earnings

Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

ABBV

ORHB

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share